Ozempic, Wegovy, and Zepbound deliver real health benefits and represent solid value for money, according to independent health economists. Yet insurance companies are locking millions of Americans out of these medications anyway, and the reason has nothing to do with whether they work.
The contradiction reveals a gap between what's medically smart and what's financially tolerable. A recent analysis from the Institute for Clinical and Economic Review, a nonprofit that grades medical treatments, confirmed that GLP-1 drugs are cost-effective, meaning the health gains justify their price tags. But cost-effective does not mean affordable for insurers trying to manage their budgets.
Researchers at the University of Mississippi drilling into this problem found the real culprit: scale. About 40 percent of Americans have obesity, and even if only a fraction of them started taking these drugs, insurance companies would face staggering new costs. One expert calculated that GLP-1 coverage could blow past a standard budget-impact threshold of 821 million dollars in a single year.
"The ICER report shows that GLP-1s provide tremendous value to society," said Sujith Ramachandran, an associate professor of pharmacy administration. "But the impact they create on the budget is still massive."
Proponents of broader access argue that treating obesity now could prevent costlier health crises down the road, reducing spending on heart disease, liver disease, and kidney problems. Insurers love that theory, but there's a problem: nobody has proven it actually happens.
Current research doesn't show that GLP-1 treatment leads to long-term savings, Ramachandran said. Many patients stop taking the drugs within a year due to cost, side effects, or simply reaching their weight loss goal. Once they quit, the weight often returns.
For insurers to see financial payoff, patients would need to stay on the medication for extended periods and maintain their results. That likely requires more than a monthly injection. Clinical trials tested these drugs alongside intensive lifestyle support, including dietitian access, gym memberships, and fitness coaching. Replicating that setup outside research settings would add significant cost and complexity.
When insurance coverage remains out of reach, cheaper compounded versions of these drugs flood the market. That creates a dangerous alternative. Unlike FDA-approved medications, compounded GLP-1 products skip rigorous manufacturing standards and quality checks. The FDA has already warned about compounded GLP-1 sellers offering unapproved ingredients or the wrong ones entirely.
"You don't know where ingredients come from or how they've been transported or handled," warned Liang-Yuan Lin, a doctoral researcher studying compounded pharmacies. "That could be really dangerous."
Industry observers expect coverage to narrow further in most cases, even as insurers may expand access for specific conditions like sleep apnea combined with diabetes or dangerously high BMI. For everyone else seeking these medications, the path forward remains blocked by arithmetic that works against patients.
Author Jessica Williams: "Insurers are trapped between promising science and unpayable bills, and patients pay the price in the meantime."
Comments